ATE230417T1 - Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien - Google Patents

Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien

Info

Publication number
ATE230417T1
ATE230417T1 AT97905136T AT97905136T ATE230417T1 AT E230417 T1 ATE230417 T1 AT E230417T1 AT 97905136 T AT97905136 T AT 97905136T AT 97905136 T AT97905136 T AT 97905136T AT E230417 T1 ATE230417 T1 AT E230417T1
Authority
AT
Austria
Prior art keywords
allergies
treatment
vaccination against
peptide immunogens
mimotope peptides
Prior art date
Application number
AT97905136T
Other languages
English (en)
Inventor
Franz Kricek
Beda Stadler
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26308839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE230417(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9604412.8A external-priority patent/GB9604412D0/en
Priority claimed from GBGB9617702.7A external-priority patent/GB9617702D0/en
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE230417T1 publication Critical patent/ATE230417T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97905136T 1996-03-01 1997-02-28 Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien ATE230417T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9604412.8A GB9604412D0 (en) 1996-03-01 1996-03-01 Organic compounds
GBGB9617702.7A GB9617702D0 (en) 1996-08-22 1996-08-22 Organic compounds
PCT/EP1997/001013 WO1997031948A1 (en) 1996-03-01 1997-02-28 Peptide immunogens for vaccination against and treatment of allergy

Publications (1)

Publication Number Publication Date
ATE230417T1 true ATE230417T1 (de) 2003-01-15

Family

ID=26308839

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905136T ATE230417T1 (de) 1996-03-01 1997-02-28 Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien

Country Status (24)

Country Link
US (1) US6610297B1 (de)
EP (1) EP0885244B2 (de)
JP (2) JP3421970B2 (de)
KR (2) KR100584051B1 (de)
CN (1) CN1174998C (de)
AT (1) ATE230417T1 (de)
AU (1) AU719609B2 (de)
BR (1) BR9707819A (de)
CA (1) CA2245497C (de)
CY (1) CY2457B1 (de)
CZ (1) CZ299551B6 (de)
DE (1) DE69718150T3 (de)
DK (1) DK0885244T4 (de)
ES (1) ES2190799T5 (de)
HU (1) HUP9901109A3 (de)
IL (1) IL125590A (de)
NO (1) NO321043B1 (de)
NZ (1) NZ331651A (de)
PL (1) PL187209B1 (de)
RU (1) RU2193413C2 (de)
SI (1) SI0885244T2 (de)
SK (1) SK284856B6 (de)
TR (1) TR199801722T2 (de)
WO (1) WO1997031948A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1621209A3 (de) * 1998-11-02 2006-04-19 Resistentia Pharmaceuticals AB Vakzinen die auf Domänen von chimären Immunoglobulin E Peptide basieren
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
EP1156825A2 (de) * 1999-02-25 2001-11-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogene enthaltend ein peptid und einen von h.influenzae protein d abstammenden träger
EP1155038A1 (de) * 1999-02-25 2001-11-21 SMITHKLINE BEECHAM BIOLOGICALS (S.A.), formerly SMITHKLINE BIOLOGICALS (S.A.) Epitope und mimotope deriviert von den c-epsilon-3 oder c-epsilon-4 domänen von ige, deren antagoniste, und deren therapeutische verwendungen
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
CA2405290C (en) * 2000-04-13 2011-06-21 Bio Life Science Forschungs Und Entwicklungsgesellschaft Mbh Vaccine against cancerous diseases
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
EP1195161A3 (de) 2000-08-30 2002-07-24 Pfizer Products Inc. Anti-IgE Vakzine
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
EP1236740B1 (de) * 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
EP1239032A1 (de) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Milchsäurebakterien als Mitteln zur Behandlung und Vorbeugung von Allergie
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
WO2003015716A2 (en) 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
IL162857A0 (en) * 2002-01-15 2005-11-20 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Oral vaccination
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
CA2487849A1 (en) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
EP2338510A1 (de) 2002-07-19 2011-06-29 Novartis Pharma AG Impfstoffzusammensetzungen, die Amyloid-beta1-6 Antigen-Arrays enthalten
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
US20050239757A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of macular degeneration
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
ATE361101T1 (de) * 2004-08-24 2007-05-15 Nutricia Nv Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
RU2340348C1 (ru) * 2007-04-04 2008-12-10 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения атопического дерматита
EP2012122A1 (de) * 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
BRPI0922561A2 (pt) 2008-12-09 2020-08-11 Pfizer Vaccines Llc vacina de peptídeo de ch3 da ige.
EP2575868A1 (de) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige-ch3-peptidimpfstoff
RU2761431C9 (ru) * 2020-10-26 2022-04-18 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Рекомбинантный полипептид на основе аллергена пыльцы березы и аллергена яблока в качестве вакцины от аллергии

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2602443A1 (de) 1975-04-04 1976-10-21 Univ California Biologisch aktive polypeptide
US4171299A (en) 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
DE2861593D1 (en) 1977-06-29 1982-03-11 Beecham Group Plc Peptides, pharmaceutical compositions containing the peptides and a process for the preparation of the peptides
JPS5944399A (ja) 1982-09-07 1984-03-12 Takeda Chem Ind Ltd 新規ｄｎａ
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
EP0269455A3 (de) 1986-11-28 1989-09-06 Takeda Chemical Industries, Ltd. Hochgereinigtes Fusionsprotein, das ein menschliches IgE Fc-Fragment enthält, sowie dessen Herstellung
AU1484688A (en) 1987-02-20 1988-09-14 Imclone Systems, Inc. Monoclonal antibodies in vaccine formulations
CA1336818C (en) 1987-04-16 1995-08-29 International Institute Of Cellular And Molecular Pathology Treatment of allergy and composition thereof
IE81146B1 (en) 1987-10-13 2000-05-03 Terrapin Tech Inc Method to produce immunodiagnostic reagents
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
US5342924A (en) 1987-12-31 1994-08-30 Tanox Biosystems, Inc. Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
CA2074089C (en) 1990-01-23 2001-04-10 Tse-Wen Chang Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
CA2082529A1 (en) 1990-05-25 1991-11-26 Denis R. Stanworth Immunodiagnostic assay for rheumatoid arthritis
US5258289A (en) 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
GB9101550D0 (en) 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
ES2193136T3 (es) * 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
GB9125024D0 (en) 1991-11-25 1992-01-22 Kirby Julian Rheumatoid arthritus treatment
JPH06113881A (ja) 1992-10-07 1994-04-26 Snow Brand Milk Prod Co Ltd ヒト型モノクローナル抗ペプチド抗体及びこれをコードするｄｎａ
WO1994025060A1 (en) 1993-04-27 1994-11-10 Ladd Anna E Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
AU6909194A (en) 1993-05-14 1994-12-12 Board Of Regents, The University Of Texas System Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
GB9320897D0 (en) 1993-10-11 1993-12-01 Peptide Therapeutics Ltd Compounds useful in anti-allergy treatment
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
FR2715304B1 (fr) 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
AU2195395A (en) * 1994-03-28 1995-10-17 United Biomedical Inc. Synthetic peptide based immunogens for the treatment of allergy
WO1996001643A1 (en) 1994-07-08 1996-01-25 Thomas Jefferson University IgE ANTAGONISTS
AU4012095A (en) 1994-10-25 1996-05-15 United Biomedical Inc. Synthetic ige membrane anchor peptide immunogens for the treatment of allergy
WO1998024808A2 (en) 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
EP0955311A3 (de) 1998-04-09 2000-08-16 Idexx Laboratories, Inc. Peptidscher Impfstoff für Hundenallergie
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens

Also Published As

Publication number Publication date
KR100498198B1 (ko) 2005-09-09
KR19990087425A (ko) 1999-12-27
JP2003231696A (ja) 2003-08-19
HK1014962A1 (en) 1999-10-08
DE69718150D1 (de) 2003-02-06
EP0885244B1 (de) 2003-01-02
HUP9901109A3 (en) 1999-11-29
WO1997031948A1 (en) 1997-09-04
AU719609B2 (en) 2000-05-11
CZ299551B6 (cs) 2008-08-27
TR199801722T2 (xx) 1998-12-21
ES2190799T5 (es) 2008-08-16
HUP9901109A2 (hu) 1999-07-28
PL328858A1 (en) 1999-03-01
JP2000502571A (ja) 2000-03-07
US6610297B1 (en) 2003-08-26
DK0885244T3 (da) 2003-04-22
IL125590A0 (en) 1999-03-12
BR9707819A (pt) 1999-07-27
DE69718150T3 (de) 2009-03-05
NO983999L (no) 1998-11-02
KR20050049509A (ko) 2005-05-25
CA2245497A1 (en) 1997-09-04
KR100584051B1 (ko) 2006-05-30
CN1213380A (zh) 1999-04-07
SI0885244T2 (sl) 2008-10-31
JP3421970B2 (ja) 2003-06-30
ES2190799T3 (es) 2003-08-16
NZ331651A (en) 2000-01-28
NO983999D0 (no) 1998-08-31
DK0885244T4 (da) 2008-06-16
CY2457B1 (en) 2005-06-03
SK118198A3 (en) 1999-03-12
RU2193413C2 (ru) 2002-11-27
PL187209B1 (pl) 2004-06-30
SK284856B6 (sk) 2006-01-05
NO321043B1 (no) 2006-03-06
AU1879697A (en) 1997-09-16
IL125590A (en) 2001-08-26
EP0885244B2 (de) 2008-04-16
CZ277198A3 (cs) 1998-12-16
DE69718150T2 (de) 2003-08-21
CN1174998C (zh) 2004-11-10
SI0885244T1 (en) 2003-06-30
EP0885244A1 (de) 1998-12-23
CA2245497C (en) 2009-02-24

Similar Documents

Publication Publication Date Title
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
CY1107578T1 (el) Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων
DE69533855D1 (de) UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG
DE69912815D1 (de) Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien
ATE331037T1 (de) Isoliertes frpb nukleinsäuremolekül und entsprechende impfstoff
DE69534325D1 (de) Peptide zur behandlung von krebs
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ATE283920T1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE60044539D1 (de) Impfstoff enthaltend lactobacilli zur behandlung von entzündungen der prostata und gutartigen prostata-hyperplasien
EP1353686A4 (de) Mhcklasse-iassoziierte peptide zur prävention und behandlung von tuberkulose
DE60030593D1 (de) Labdan-enthaltende arzneiformulierungen zur behandlung von tumoren oder leukämien
DE60037349D1 (de) Zusammensetzungen und Verfahren zur Behandlung von Tumoren

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0885244

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0885244

Country of ref document: EP

REN Ceased due to non-payment of the annual fee